Publications by authors named "Maximilian Meuer"
Front Cardiovasc Med
December 2022
Article Synopsis
- - Gliflozins, which target the SGLT2 protein in kidneys, show promise for treating type II diabetes by improving glucose control and reducing cardiovascular and renal risks, particularly in patients with heart dysfunction.
- - A systematic review of 29 studies involving over 88,000 patients found that gliflozins significantly lowered the rates of heart failure-related hospitalizations and combined heart failure events with cardiovascular death.
- - Sotagliflozin was identified as more effective in preventing certain risks associated with heart failure and cardiovascular events compared to other gliflozins like ertugliflozin, dapagliflozin, and empagliflozin.
